Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Intranasal delivery of a bivalent norovirus vaccine formulated in an in situ gelling dry powder

  • Jordan P. Ball,

    Affiliation Research and Development Department, Nanotherapeutics, Inc., Alachua, Florida, United States of America

  • Michael J. Springer,

    Affiliation Research and Development Department, Nanotherapeutics, Inc., Alachua, Florida, United States of America

  • Yawei Ni,

    Affiliation Research and Development Department, Nanotherapeutics, Inc., Alachua, Florida, United States of America

  • Isaac Finger-Baker,

    Affiliation Research and Development Department, Nanotherapeutics, Inc., Alachua, Florida, United States of America

  • Juan Martinez,

    Affiliation Research and Development Department, Nanotherapeutics, Inc., Alachua, Florida, United States of America

  • Jessica Hahn,

    Affiliation Research and Development Department, Nanotherapeutics, Inc., Alachua, Florida, United States of America

  • John F. Suber,

    Affiliation Research and Development Department, Nanotherapeutics, Inc., Alachua, Florida, United States of America

  • Ashley V. DiMarco,

    Affiliation Research and Development Department, Nanotherapeutics, Inc., Alachua, Florida, United States of America

  • James D. Talton,

    Affiliation Research and Development Department, Nanotherapeutics, Inc., Alachua, Florida, United States of America

  • Ronald R. Cobb

    Affiliation Research and Development Department, Nanotherapeutics, Inc., Alachua, Florida, United States of America


Intranasal delivery of a bivalent norovirus vaccine formulated in an in situ gelling dry powder

  • Jordan P. Ball, 
  • Michael J. Springer, 
  • Yawei Ni, 
  • Isaac Finger-Baker, 
  • Juan Martinez, 
  • Jessica Hahn, 
  • John F. Suber, 
  • Ashley V. DiMarco, 
  • James D. Talton, 
  • Ronald R. Cobb


The global health community is beginning to understand the burden of norovirus-associated disease, which has a significant impact in both developed and developing countries. Norovirus virus like particle (VLP)-based vaccines are currently under development and have been shown to elicit systemic and mucosal immune responses when delivered intranasally. In the present study, we describe the use of a dry powder formulation (GelVac) with an in situ gelling polysaccharide (GelSite) extracted from Aloe vera for nasal delivery of a bivalent vaccine formulation containing both GI and GII.4 norovirus VLPs. Dose-ranging studies were performed to identify the optimal antigen dosages based on systemic and mucosal immune responses in guinea pigs and determine any antigenic interference. A dose-dependent increase in systemic and mucosal immunogenicity against each of the VLPs were observed as well as a boosting effect for each VLP after the second dosing. A total antigen dose of ≥50 μg of each GI and GII.4 VLPs was determined to be the maximally immunogenic dose in guinea pigs. The immunogenicity results of this bivalent formulation, taken together with previous work on monovalent GelVac norovirus vaccine formulation, provides a basis for future development of this norovirus VLP vaccine.


Viruses belonging to the genus Norovirus are responsible for over 90% of all non-bacterial gastroenteritis epidemics and are a leading cause of global diarrhea [17]. Norovirus accounts for approximately 23 million infections per year [4] and approximately 220,000 deaths in developing countries [8, 9]. Although norovirus affects all ages, children younger than 5 years [5, 10], the elderly [11], and immunocompromised persons [12] are at greatest risk. There is a need for a prophylactic norovirus vaccine and promising virus-like particle (VLP)-derived vaccine candidates are under development [1319]. The genetic and antigenic diversity of noroviruses are a challenge to vaccine development with more than 30 genotypes within genogroups I (GI) and II (GII) [2022] known to infect humans. Due to this wide variation, development of a broadly effective vaccine remains a challenge as the antibodies from humans immunized against one genogroup do not cross react with noroviruses from other genogroups [23]. Recently, genogroup II has become the most prevalent, accounting for 81.4% of norovirus outbreaks worldwide [24]. Several recently described cell culture systems for human norovirus have not been replicated or have only shown limited viral replication [2528]. However, a recent report demonstrates that viral replication was established in human intestinal epithelial cells [29]. This new cell culture system will allow the development of new methods to assess the efficacy of new treatment regimens for norovirus infections. To date, these systems have not been developed sufficiently to support large scale viral production. Norovirus VLPs, either expressed in plants or insect cells which are structurally and morphologically similar to the native virus, are widely used as a source of norovirus antigen [14, 15, 18, 19, 30, 31].

Establishment of a clear immune correlate of protection has been an obstacle toward the development of such vaccine candidates. Research has shown that histo-blood group antigens (HBGAs) serve as attachment factors or receptors for noroviruses in a genotype specific manner [13, 32, 33]. In addition, the lack of HBGAs were shown to restrict viral replication [29]. Histo-blood group antigens are complex carbohydrates expressed on red blood cells and, in individuals with a functional fucosyltransferase 2 (FUT 2) gene, also on mucosal surfaces and body secretions [34]. An established correlate of protection to norovirus infection is the ability of serum and mucosal antibodies to block binding of norovirus VLPs to HBGAs [31, 35, 36]. Norovirus specific serum IgGs alone were not protective in challenge models in humans [35, 37, 38]. In contrast, norovirus specific serum IgA and salivary IgA levels have been associated with protection against norovirus gastroenteritis [35, 39, 40]. Previous studies have shown different B- and T-cell responses are observed in mice immunized intranasally and intramuscularly with norovirus VLPs [41]. Recent studies have shown that mucosal IgA antibodies are induced by intranasal administration of norovirus VLPs and not by intramuscular administration [36].

Previous studies have shown that the incorporation of VLPs with GelVac nasal dry powder formulation is able to increase antigen availability and induce systemic immunity as well as both local and distal mucosal immunity [16, 19]. Intranasal immunization of guinea pigs with the GelVac norovirus vaccine resulted in high levels of mucosal IgA and serum IgG antibodies in a dose-dependent manner [14, 16]. The present study investigating a bivalent norovirus vaccine extends the previous work with monovalent vaccine formulations [14, 16] and demonstrates that a GelVac formulated bivalent norovirus GI/GII.4 VLP vaccine induces high levels of antigen-specific systemic and mucosal antibodies in a dose-dependent manner to both GI and GII.4 VLPs. The bivalent GelVac norovirus vaccine formulation also induced neutralizing antibodies to both GI and GII.4 VLPs in a similar fashion as that observed in previous studies [14]. The results presented in the present study form the basis for future studies to investigate a bivalent GelVac GI/GII.4 norovirus vaccine formulation for the prevention of norovirus-induced gastroenteritis in humans.

Materials and methods

GI and GII.4 vaccine formulation

Recombinant norovirus GI (8K/1979/USA) and GII.4 (Minerva/2006/USA) VLPs, consisting solely of the VP1 major capsid protein, were expressed in Spodoptera frugiperda (Sf9) using the baculovirus expression system (Invitrogen Life Technologies, Carlsbad, CA). Sf9 cells were cultured at the 1 L scale and infected with baculovirus clones encoding for GI or GII.4 VLPs at a multiplicity of infection of 0.1 at a cell density above 1x106 cells/mL. The infected cells were cultured until the viable cell density was <30% (approximately 4–5 days). Primary clarification was performed by Millistak+ HC μPod D0HC depth filtration media (23 cm2), (Millipore, Billerica, MA) followed by microfiltration through an Opticap XL150 Millipore Express SHC (0.5/0.2 μm) filter (Millipore, Billerica, MA). Clarified supernatant was diluted 3-fold with 50 mM sodium acetate, pH 5.0 for cation exchange chromatography.

Cation exchange chromatography was performed on POROS HS50 resin using an Akta Avant 150 chromatography skid (GE Life Sciences, Marlborough, MA). After equilibration with 20 mM sodium acetate buffer, pH 5.0, clarified supernatant was loaded at 300 cm/hr, washed with 20 mM sodium acetate buffer and eluted with a linear gradient of NaCl (0 to 1 M NaCl). Purified drug substance was ultrafiltered using a 100 kDa Vivaflow 50 and diafiltered with Mg2+, Ca2+-free PBS (Sartorius, Bohemia, NY). Samples were analyzed by SDS-PAGE, western blot, and ELISA for GI/GII.4 norovirus VLP content.

The size of the stock VLP particles was determined using transmission electron microscopy at University of Florida, Interdisciplinary Center for Biotechnology Research, Electron Microscopy and Bio-imaging Core. VLP stocks were diluted in water for imaging. Carbon coated Formvar copper grids, 400 mesh were glow discharged with Pelco easiGlow unit. Samples were incubated on the grids for 5 minutes. Excess solution was removed with filter paper. The sample grid was then incubated with 1% aqueous uranyl acetate 30 seconds. Excess stain was removed with filter paper, air dried, and examined with a Hitachi H-7000 TEM (Hitachi High Technologies America, Inc. Schaumburg, IL) and digital images acquired with a Veleta 2k x 2k camera and iTEM software (Olympus Soft-Imaging Solutions Corp, Lakewood, CO).

The particle size distribution for each of the powders was performed by using a 50 mg sample of each powder and suspending it in 100% isopropanol. Particle size distribution, by volume, was determined using a laser diffraction particle size analyzer with a liquid module (Beckman Coulter LS13-320, Pasadena, CA). Performance of the instrument was verified using a 35 μm garnet reference standard.

The GelVac vaccine powders were produced using a lyophilization-milling method. Norovirus VLPs were formulated in liquid using a proprietary formulation in GelSite® polymer and then lyophilized. The dried formulation contained 0.25% (w/w) GelSite® polymer and various amounts of VLP (based on BCA and ELISA data). Placebo control powders were formulated in a similar manner but did not contain VLPs. Each individual formulation was milled using a mortar and pestle in a controlled environment (< 10% relative humidity) and passed through a 70 μM filter. The doses were stored in sealed containers room temperature under desiccation prior to use. The non-adjuvanted GelVac vaccine dry powders were produced in sufficient quantity for the entire study and characterized using ELISA, SDS-PAGE and western blot data as previously described and shown to be greater than 95% pure [14]. Final dosages were calculated based on ELISA data as previously described [14].

Animal studies

The animal protocols used in this study were approved by the Institutional Animal Care and Use Committee at the University of Florida. The Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International recommendations were followed for general procedures with respect to animal care and housing. Female Hartley guinea pigs (Harlan Laboratories), six to eight weeks of age and 200–250 g were utilized for these studies. Animals were allowed to acclimate for two weeks prior to study. Animals were fed commercial guinea pig food and Timothy hay once per day and water was provided ad libitum. Animals were not fasted overnight prior to each administration of vaccine. Animals were monitored daily and weighed twice weekly throughout the study. Female (350 g) Hartley guinea pigs obtained from Harlan Laboratories were selected as the model animal for evaluation of the intranasal dry power delivery. Varying concentrations of a GelVac dry powder vaccine containing both GI and GII.4 VLPs were used to observe the dose response of guinea pigs (Table 1).

Animals were randomly distributed into study groups (n = 4) and allowed to acclimate for two weeks, prior to immunization. Each study consisted of seven study groups, one for placebo powders and four for GelVac VLP bivalent dry powder vaccines at different antigen dose levels and two monovalent vaccine formulations. Each animal group received an enumerated dose of antigens suspended in GelVac deposition powder on an administration day. Powder vaccines were administered intranasally on days 0 and 21 with 10 mg/nare of dry powder formulation. Each bivalent dose and monovalent controls had a total amount of each antigen as described in Table 1 (e.g. in Group 4, 5 μg GI and 5 μg GII.4 antigens in the total administration dose). The control dosage was based upon previous data [14, 16]. Aptar Unit Dose Spray (UDS) Devices (Aptar Pharma, Congers, NY) equipped with small animal adapters were each loaded with 10 mg of vaccine powder were used for intranasal powder delivery. Delivery of greater than 92% of the powder has been demonstrated using these devices (data not shown). Guinea pigs were anesthetized with 5% isoflurane prior to immunization and sample collection. While under anesthesia, each animal was given two administrations of VLP powders, one per nare with half of the total antigen dose per nare (10 mg total powder per nare). A placebo powder formulation was administered similarly to the control group.

Guinea pig serum and vaginal lavage samples were collected on days 0 (preimmunization), 21 (preimmunization), 42, and 56. Blood, (1 mL/collection period) was collected from the superior vena cava and allowed to coagulate in serum separation tubes. Serum was collected as the supernatant after centrifugation for 10 min at 6000 rpm. Vaginal lavages were collected by lavaging 300 μL of PBS for 60 s in the vaginal tract with an oral feeding tube. Gastrointestinal samples were obtained on day 56. On day 56, guinea pigs were maintained under 5% isoflurane and exsanguinated by cardiocentesis. Gastrointestinal samples were collected by lavaging the 12 cm of the small intestines by passing 1 mL of PBS through the area three times. All samples were clarified by centrifugation for 10 min at 6000 rpm and stored at -20°C prior to analysis.

ELISA for serum and mucosal antibodies

ELISA for serum and mucosal antibodies were performed as previously described [14]. Briefly, VLPs in PBS were incubated on Nunc MaxiSorp 96-well plates (Fisher Scientific) for 4 h at room temperature. The plates were blocked overnight at 4°C. All samples were serially diluted 2-fold and allowed to incubate at room temperature for 1 h. Plates were washed 5 times, followed by incubation with anti-guinea pig IgG-HRP (Southern Biotech, Birmingham, AL at 1:1000, anti-guinea-pig IgA (Creative Diagnostics, Shirley, NY) at 1:1000, anti-guinea pig IgG1 HRP (Antibodies Online) at 1:1000, or anti-guinea pig IgG2 RP (Antibodies Online) at 1:2000 for 1 h at room temperature. The plates were washed 5 times and developed with 1-step Ultra TMB according to the manufacturer’s protocol. End-point titers were reported as the reciprocal of the highest dilution that produced an OD of 0.1 above background and presented as Geometric Mean Titers. ositive control serum generated in guinea pigs against GI or GII.4 was included in each test run to confirm reproducibility.

Gastric mucin ligand-binding serum neutralization assay

Porcine Gastric Mucin Type III (PGM) (Sigma Aldrich) has been previously used as a substrate for norovirus VLP antibody-blockade assays [42, 43]. Gastric mucin ligand-binding serum neutralization assays were performed as described. [14]. Briefly, PGM was dissolved in PBS at a final concentration of 5 mg/mL and 100 μL was added to each well of a 96-well MaxiSorp plate and incubated 4 h at room temperature. The wells were blocked overnight at 4°C. Serum samples were serially diluted and norovirus GI or GII.4 VLPs were added to the hyperimmune serum (0.25 μg/mL) and incubated for 1 h at room temperature. A total of 100 μL of the VLP-hyperimmune serum was added to each well and incubated for 1 h at room temperature. The wells were washed 5 times followed by the addition of goat-anti-mouse-HRP conjugate antibody (Milllipore, 1:2000 dilution) and incubated 1 h at room temperature. Plates were developed using 1-step Ultra TMB substrate according to the manufacturer’s protocol. Each serum sample was tested in 2-fold serial dilution and neutralizing titers were reported as the inflection of the curve (50% reduction, EC50) as indicated by the 4-Parameter Logistics fit.


SoftMax Pro 4.8 was used for sigmoidal curve fits. Two-way analysis of variance (ANOVA) models were fit separately to each sample type (serum, neutralizing, and vaginal lavage) (GraphPad Prism 7.01 Software, La Jolla, CA). Each titer was transformed by taking the base-10 logarithm of the measurement values. Tukey’s post-hoc test for multiple comparisons was used to compare each dose group (GraphPad Prism 7.01 Software). All results are reported based on the p ≤ 0.05 level of significance.


GelVac vaccine powder characterization

The GelVac bivalent nonovirus vaccine powder was manufactured and characterized as previously described and shown to be greater than 95% pure [14]. The analytical characterization of the bivalent vaccine demonstrated that the bivalent powder was as described in previous work [14]. Norovirus GI and GII.4 VLP stocks were analyzed for the presence of intact VLPs by transmission electron microscopy prior to powder formulation. The results confirmed the presence of intact VLPs of the expected sized for both GI (32.6 ± 6 nm) and GII.4 (28.9 ± 9 nm) VLP stocks (Fig 1).

Fig 1. Transmission electron microscopy of norovirus VLPs.

GI (A) and GII.4 (B) VLPs were dissolved in water and imaged at 150,000x magnification (scale bar 100 μm). VLP particles were spherical in appearance at the expected size of 23–38 nm.

ELISAs were used to confirm the GI or GII.4 VLP dose content in the bivalent vaccine powder. The results showed that the individual powder formulations contained the expected dosage of VLPs and the presence of VLPs in vaccine powders were further confirmed by Western blot (S3B and S3C Fig) [14]. Laser diffraction particle size distribution confirmed the volumetric mean particle size to be 24–42 μm, with the d10 approximately 5–8 μm (Table 2), similar to what was observed previously [14].

Table 2. Representative volumetric particle size distribution of GI and GII.4 monovalent and bivalent vaccine powders.

Immunogenicity of bivalent GelVac norovirus vaccine

Dose-dependent immune responses were investigated with bivalent GelVac vaccine formulations containing GI and GII.4 norovirus VLPs. Animals were dosed on days 0 and 21 with varying amounts of the bivalent norovirus GI and GII.4 VLPs (Table 1). Serum and vaginal lavage samples were collected from the animals on days 0 (pre-immunization), 21 (pre-immunization), 42, and 56. Intestinal lavage was collected upon termination of the study (day 56). No animals became ill or died at any time prior to the experimental endpoint. There was only one animal from the 50 μg dose group that appeared to be a non-responder. The data from this animal was included in the final data analyses.

Serum antibody response.

Serum samples exhibited a dose-dependent increase in total antigen specific IgG antibodies with the bivalent vaccine powder for both GI and GII.4 antigens (Fig 2). IgG titers in serum increased on day 21 and a further increase was observed on day 42 at all doses > 5 μg as compared to the control group. At day 21, a significant difference between the 100 μg dose group and the placebo control was observed (S1S5 Tables). By day 42 all dose groups containing GI VLP exhibit a significantly higher IgG titer than the placebo and by day 56, all groups ≥ 15 μg exhibit a significant increase over placebo (Fig 2A). No significant differences were observed between the GI monovalent test group and the 50 μg bivalent test group indicating there is likely no appreciable interference from the inclusion of the GII.4 VLPs. By day 42, GI IgG titers increased by >25-fold compared to placebo which was sustained to day 56. Similar results were observed for GII.4 IgG titers with an increase of ≥ 30-fold at day 21 and up to ≥ 700-fold by day 42 (Fig 2B). No significant differences were observed between the GII.4 monovalent test group and the 50 μg bivalent test group indicating there is likely no appreciable interference from the inclusion of the GI VLPs. The lowest dose that elicited an antigen specific IgG response was 5 μg for both GI and GII.4 which corresponded to a titer of 30800 and 245840 on day 56, respectively.

Fig 2. Serum norovirus-specific IgG and IgA production following intranasal immunization with GelVac bivalent and monovalent vaccine powders.

Female Hartley guinea pigs were immunized intranasally with 20 mg of a bivalent vaccine powder formulation containing various amounts of GI and GII.4 VLPs on days 0 and 21. Serum samples were collected on day 0, 14, 21, 42, and 56 and analyzed for specific IgG antibodies against GI (A) and GII.4 (B). Serum samples were also analyzed for specific IgA antibodies against GI (C) and GII.4 (D). Error bars are provided as geometric standard deviation. *p<0.05 as compared to the placebo control group. Horizontal dotted line depicts the limit of detection for these assays.

This study also included measurement antigen specific IgA titers in serum by ELISA. At day 42, anti-GI and anti-GII.4 specific VLP IgA antibodies were observed at all doses that were administered when compared to placebo (Fig 2). At day 56, bivalent dose groups of 5, 15, and 50 μg showed a significantly higher titer than the placebo group for the GII.4 antigen. These results demonstrated that the bivalent GI/GII.4 VLP vaccine formulations were highly immunogenic when compared to placebo control.

IgG subclasses IgG1 and IgG2 were measured by ELISA using the pooled serum samples from each group (S4 Fig). GI and GII.4 IgG2 specific titers were shown to be qualitatively higher than GI or GII.4 IgG1 specific titers at day 21. IgG1 and IgG2 boosting effects were observed for both GI and GII.4 at day 42. Overall, the IgG2 titers were higher than IgG1 titers for both GI and GII.4 VLPs. These results show that the bivalent GI/GII.4 VLP vaccine formulations were highly immunogenic relative to the placebo control and capable of producing a wide range of antibody responses.

Serum neutralization antibody response.

Antigen specific antibodies were investigated for their ability to inhibit the binding of the norovirus VLPs to porcine gastric mucin. The neutralizing antibodies present in the serum exhibited a dose-dependent response similar to that observed for antigen specific IgG antibody titers (Fig 3). GI neutralizing antibody titers were elevated in the 50 μg and 100 μg dose groups by day 42 with similar titers observed at day 56 as compared to the placebo group. GII.4 neutralizing antibody titers were elevated for all groups by day 42 with similar titers observed at day 56. Comparable to the serum IgG results, the 50 μg bivalent dose group did not show a significant difference from the monovalent dose groups in their respective assays, suggesting that interference in the bivalent formulation is unlikely. By day 42, GI neutralizing antibody titers increased by > 10-fold for all bivalent dose groups ≥ 15 μg and GII.4 neutralizing antibody titers increased by > 14-fold for all dose groups ≥ 5 μg, consistent with the findings with serum IgG titers. The lowest dose that produced a detectable neutralization titer at day 56 was 15 μg for GI and 5 μg for GII.4. The neutralizing antibody titers followed a similar dose-dependent response to that observed for the total serum IgG titers.

Fig 3. Neutralizing antibody production following intranasal immunization with GelVac dry powder bivalent and monovalent vaccine.

Female Hartley guinea pigs were immunized intranasally with 20 mg of a bivalent vaccine powder formulation containing various amounts of GI and GII.4 VLPs on days 0 and 21. Serum samples were collected on days 0, 14, 21, 42, and 56 and analyzed for GI (A) and GII.4 (B) neutralizing antibodies. Error bars are provided as geometric standard deviation. *p<0.05 as compared to the placebo control group. Horizontal dotted line depicts the limit of detection for these assays.

Mucosal antibody response.

Mucosal antibody titers were evaluated in the reproductive tracts and intestines to investigate the mucosal immune response to the bivalent vaccine (Fig 4). GI and GII.4 vaginal IgG antibody titers were elevated in 50 μg and 100 μg dose groups by day 21 when compared to controls, and in all dose groups greater than 5 μg by day 56. GII.4 vaginal antibody titers were elevated in the 5 μg, 15 μg, 50 μg, and 100 μg dose groups by day 42 with significant increases over placebo in bivalent doses ≥ 15μg. Both GI and GII.4 elicited a response in mucosal IgG at the lowest dose group of 5 μg. The highest vaginal antibody titers occurred at 50 μg for both GI and GII.4. These results showed that vaginal IgG antibody titers exhibited a dose-dependent response. GI and GII.4 specific IgG titers were also observed in the intestines at day 56 (Fig 4C and 4D). As shown, antibody titers were observed in all treatment groups for both GI and GII.4 specific antibodies. Significant increases over controls in the 50 μg dose group and ≥ 5 μg dose groups were observed for GI and GII.4, respectively.

Fig 4. Mucosal norovirus-specific antibody production following intranasal immunization with GelVac dry powder bivalent and monovalent vaccine.

Female Hartley guinea pigs were immunized intranasally with 20 mg of a bivalent vaccine powder formulation containing various amounts of GI and GII.4 VLPs on days 0 and 21. Vaginal lavage samples were collected on days 0, 14, 21, 42, and 56 and analyzed for GI (A) and GII.4 (B) norovirus-specific antibodies. On day 56, animals were euthanized and intestinal lavage samples were analyzed for GI (C) and GII.4 (D) norovirus-specific antibodies. Error bars are provided as geometric standard deviation. *p<0.05 as compared to the placebo control group. Horizontal dotted line depicts the limit of detection for these assays.


Human noroviruses cause acute, debilitating gastroenteritis characterized by vomiting and diarrhea. The US Centers of Disease Control and Prevention estimate it is the leading cause of epidemic non-bacterial gastroenteritis in the US. Multiple vaccine strategies, mostly relying on VLP antigens, have demonstrated proof of efficacy in human challenge studies [18, 4448]. Previous studies have demonstrated that a norovirus VLP GelVac dry powder vaccine produces a robust systemic and mucosal immune response [14, 16]. In the present study, we describe the systemic, mucosal, and neutralizing antibody responses to a GelVac dry powder bivalent norovirus vaccine containing varying amounts of both GI and GII.4 norovirus VLP antigens.

Guinea pigs were used in this study due to the intranasal powder delivery system that we employed. Previous studies [16] have used six animals per group and demonstrated similar levels of significance as demonstrated in the present study. In addition, studies by Baric and his laboratory also used four animals per group [49] and our previous work [14]. For these reasons, four animals per group were used throughout this study.

The results depict that the bivalent vaccine powder induced a dose-dependent antibody response against GI and GII.4 VLPs without exhibiting interference from either antigen. Antigen specific IgG antibody titers present in serum samples increased with greater amounts of both GI and GII.4 VLP antigens present in the powder and reached a maximal level at 50 μg of VLP antigen. Higher doses of VLPs did not result in significantly higher titers of antigen specific IgGs in either serum or mucosal. Additionally, a boosting effect on systemic and mucosal antigen specific IgGs and IgAs was observed for each VLP antigen after the second powder administration on day 21.

A surrogate marker for efficacy identified that correlates well with protection in humans and chimpanzees is the production of antibodies that neutralize HBGA binding sites [31, 35, 50]. In particular, previous studies have shown the levels of IgA in mucosal tissues was strongly correlated with the blocking activity, suggesting that IgA, but not IgG, was the major norovirus blocking antibody on the mucosal surface [36]. In addition, it has been shown that only mucosal immunization induces the development of functional anti-norovirus IgA on mucosal surfaces [36]. The data presented herein demonstrated that the GelVac bivalent norovirus intranasal vaccine powder containing both GI and GII.4 VLPs was capable of producing antibodies that inhibited the binding of the VLPs to pig gastric mucin. A dose-dependence was observed for these neutralizing antibodies with the amount of GI or GII.4 VLP administered. Furthermore, neutralizing antibody titers demonstrated a boosting effect after the second dose in a similar fashion as observed for serum IgG antibodies. An increased VLP antigen dose was required for the production of neutralizing antibody titers as compared to the induction of total specific IgG antibodies. A dose of at least 50 μg for GII.4 and 50 μg for GI VLP antigen was required to raise the production of neutralizing antibodies.

Antigen specific mucosal antibody titers were determined using vaginal lavage sampling. Antigen specific IgG antibody production in the vaginal lavages showed similar trends as those observed in the intestinal tract. The antigen specific antibodies observed in these mucosal tissues also showed similar trends to titers observed in serum for both antigen specific IgG antibodies and neutralizing antibodies. IgG antibodies in the mucosa are most likely conferred through transudation of serum IgG antibodies [51]. A general link between increased serum IgG with increased vaginal lavage IgG is observed, as well as an increase in serum IgA [16, 52]. This link, coupled with the observed overall decrease in signal in vaginal lavage samples and IgA detection could contribute to mucosal IgA titers falling below the assay limit of detection. Additionally, the reagents used in previous work were not available for this study and make comparisons challenging. These results suggest that our GelVac vaccine powder is capable of inducing a mucosal response along with a neutralizing antibody response.

There are currently no licensed vaccines for norovirus. There are many factors that complicate the development of norovirus vaccines including the lack of appropriate model systems to explore vaccine target efficacy, unknown duration of protective immunity, antigenic variation and drift within genogroups and genotypes, and the unknown effects of pre-exposure history. The recent demonstration of the cultivation of norovirus in cell culture should permit human host pathogen interactions and allow assessment of various methods to prevent and treat norovirus infections [29]. Despite these limitations, vaccine feasibility has been demonstrated using norovirus VLPs in human challenge studies [17, 18]. However, these studies demonstrated only 47% efficacy in a 2-dose intranasal VLP vaccine and 52% protection in an IM administration against all severity levels of disease (p = 0.028) and 68% (p = 0.068) against moderate to severe disease. These vaccines were formulated with Aluminum Hydroxide and Monophosphoryl lipid adjuvants. These vaccines are still in clinical development. A norovirus-rotavirus protein combination vaccine is in preclinical development with promising results [15]. In addition, a novel combination construct which contains VLPs of norovirus GII.4 and enterovirus 71 has been shown to elicit functional antibodies to both viruses without evidence of interference [53]. One other intranasal norovirus vaccine is currently in development. This is based on the norovirus P particle derived from the protruding (P) domain of the norovirus VP1 capsid protein being delivered intranasally in gnotobiotic pigs [54]. The study demonstrated cross-variant protection of the P particle vaccine against human noroviral diarrhea. Despite these advances, other formulations of norovirus vaccine, such as the one described in this study, may provide advantages over the vaccines currently in development. One advantage of the current formulation over other vaccine candidates is the lack of adjuvants. The current GelVac is made from materials that the FDA has considered generally regarded as safe (GRAS). The data presented herein, as well as previous work [14, 16], demonstrate that the current vaccine candidate does not require the addition of adjuvants and is administered IN. Current studies being performed with the GelVac dry powder norovirus vaccine include a comparison of IN and IM administration.

The data presented in this study using the GelVac dry powder bivalent norovirus vaccine extends the results from previous studies [14, 16]. The data demonstrates that there was no inhibition or competition between the two VLP antigens in the bivalent GelVac nasal powder on the production of systemic and mucosal anti-norovirus specific antibodies. A dose content of 15–50 μg GI or GII.4 VLP antigen appeared to be required to produce a robust response. Future studies will be conducted with GelVac GI and GII.4 bivalent vaccine formulation administered either intranasally or intramuscularly. The results will help to demonstrate the efficacy of the intranasal formulation when compared to an intramuscular injection and determine the antigen dose for this bivalent vaccine that could be used in additional pre-clinical development.

Supporting information

S1 Fig. Thermo stability evaluation of norovirus VLPs using SYPRO orange.

VLPs were diluted in 4x SYPRO orange solution and the melt curve was analyzed using a fluorescent thermocycler. Data is plotted as the change in Fluorescence per unit Temperature. A. Norovirus GI VLP melt curve. B. Norovirus GII.4 VLP melt curve.


S2 Fig. Assessment of capture ELISA specificity to intact VLPs.

VLP samples (0.2 μg/mL) were treated at varying temperatures for 5 minutes. Each sample was then analyzed by capture ELISA.


S3 Fig. SDS-PAGE and western blot analysis of GI and GII.4 VLP in norovirus vaccine powders.

(A) (SDS-PAGE), (B) GI VLP (western blot), and (C) GII.4 VLP (western blot).


S4 Fig. Serum norovirus-specific IgG1 and IgG2 production following intranasal administration with GelVac dry powder bivalent and monovalent vaccine.

Serum samples were analyzed for norovirus-specific IgG1 antibodies against GI (A) and GII.4 (B), and norovirus-specific IgG2 antibodies against GI (C) and GII.4 (D). Horizontal dotted line depicts the limit of detection for these assays.


S1 Table. List of multiple comparison adjusted p-values for Tukey’s post hoc test for significance following a two-way analysis of variance.


S2 Table. Total antigen specific serum IgG, IgA and neutralizing antibody titers.


S3 Table. Total antigen specific serum IgG1 and IgG2 antibody titers.


S4 Table. Total antigen specific IgG titers from intestinal lavage samples.


S5 Table. Total antigen specific IgG titers from vaginal lavage samples.


Author Contributions

  1. Conceptualization: YN RRC JDT.
  2. Data curation: JPB MJS IFB RRC YN JDT.
  3. Formal analysis: JPB MJS IFB RRC YN.
  4. Funding acquisition: JDT RRC.
  5. Investigation: JPB MJS IFB JM JH JFS AVD.
  6. Methodology: RRC JDT JM YN.
  7. Project administration: RRC YN JDT.
  8. Resources: JPB IFB JM JH JFS AVD.
  9. Software: JPB.
  10. Supervision: RRC YN.
  11. Validation: RRC YN.
  12. Visualization: JPB MJS RRC YN.
  13. Writing – original draft: RRC IFB JPB.
  14. Writing – review & editing: YN JM JH JFB AVD.


  1. 1. Hedberg C. Food-related illness and death in the United States. Emerg Infect Dis. 1999;5(6):840–2. pmid:10603229;
  2. 2. Caul EO. Small round structured viruses: airborne transmission and hospital control. Lancet. 1994;343(8908):1240–2. pmid:7910270.
  3. 3. Hall AJ, Lopman BA, Payne DC, Patel MM, Gastañaduy PA, Vinjé J, et al. Norovirus disease in the United States. Emerg Infect Dis. 2013;19(8):1198–205. pmid:23876403;
  4. 4. Mead PS, Slutsker L, Griffin PM, Tauxe RV. Food-related illness and death in the united states reply to dr. hedberg. Emerg Infect Dis. 1999;5(6):841–2. Epub 1999/12/22.
  5. 5. Patel MM, Widdowson MA, Glass RI, Akazawa K, Vinje J, Parashar UD. Systematic literature review of role of noroviruses in sporadic gastroenteritis. Emerg Infect Dis. 2008;14(8):1224–31. Epub 2008/08/06. pmid:18680645;
  6. 6. Vega E, Barclay L, Gregoricus N, Shirley SH, Lee D, Vinje J. Genotypic and epidemiologic trends of norovirus outbreaks in the United States, 2009 to 2013. J Clin Microbiol. 2014;52(1):147–55. Epub 2013/11/01. pmid:24172151;
  7. 7. Verhoef L, Hewitt J, Barclay L, Ahmed SM, Lake R, Hall AJ, et al. Norovirus genotype profiles associated with foodborne transmission, 1999–2012. Emerg Infect Dis. 2015;21(4):592–9. Epub 2015/03/27. pmid:25811368;
  8. 8. Kirk MD, McKay I, Hall GV, Dalton CB, Stafford R, Unicomb L, et al. Food safety: foodborne disease in Australia: the OzFoodNet experience. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2008;47(3):392–400. Epub 2008/06/19. pmid:18558879.
  9. 9. Siqueira JA, Linhares AC, Gabbay YB. Reply to the apropos "Evaluation of third-generation RIDASCREEN enzyme immunoassay for the detection of norovirus antigens in stool samples of hospitalized children in Belem, Para, Brazil". Diagnostic microbiology and infectious disease. 2012;73(1):101–2. Epub 2012/05/15. pmid:22578944.
  10. 10. Kowalzik F, Riera-Montes M, Verstraeten T, Zepp F. The burden of norovirus disease in children in the European Union. The Pediatric infectious disease journal. 2015;34(3):229–34. Epub 2015/03/06. pmid:25742072;
  11. 11. Trivedi TK, DeSalvo T, Lee L, Palumbo A, Moll M, Curns A, et al. Hospitalizations and mortality associated with norovirus outbreaks in nursing homes, 2009–2010. Jama. 2012;308(16):1668–75. Epub 2012/10/20. pmid:23079758.
  12. 12. Bok K, Green KY. Norovirus gastroenteritis in immunocompromised patients. N Engl J Med. 2012;367(22):2126–32. Epub 2012/11/30. pmid:23190223.
  13. 13. Marionneau S, Ruvoen N, Le Moullac-Vaidye B, Clement M, Cailleau-Thomas A, Ruiz-Palacois G, et al. Norwalk virus binds to histo-blood group antigens present on gastroduodenal epithelial cells of secretor individuals. Gastroenterology. 2002;122(7):1967–77. Epub 2002/06/11. pmid:12055602.
  14. 14. Springer MJ, Ni Y, Finger-Baker I, Ball JP, Hahn J, DiMarco AV, et al. Preclinical dose-ranging studies of a novel dry powder norovirus vaccine formulation. Vaccine. 2016;34(12):1452–8. Epub 2016/02/14. pmid:26873053;
  15. 15. Tamminen K, Lappalainen S, Huhti L, Vesikari T, Blazevic V. Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in mice. PloS one. 2013;8(7):e70409. Epub 2013/08/08. pmid:23922988;
  16. 16. Velasquez LS, Shira S, Berta AN, Kilbourne J, Medi BM, Tizard I, et al. Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine. Vaccine. 2011;29(32):5221–31. pmid:21640778;
  17. 17. Atmar RL, Bernstein DI, Harro CD, Al-Ibrahim MS, Chen WH, Ferreira J, et al. Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med. 2011;365(23):2178–87. pmid:22150036;
  18. 18. Bernstein DI, Atmar RL, Lyon GM, Treanor JJ, Chen WH, Jiang X, et al. Norovirus Vaccine Against Experimental Human GII.4 Virus Illness: A Challenge Study in Healthy Adults. J Infect Dis. 2015;211(6):870–8. pmid:25210140.
  19. 19. Parra GI, Bok K, Taylor R, Haynes JR, Sosnovtsev SV, Richardson C, et al. Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations. Vaccine. 2012;30(24):3580–6. pmid:22469864;
  20. 20. Blanton LH, Adams SM, Beard RS, Wei G, Bulens SN, Widdowson MA, et al. Molecular and epidemiologic trends of caliciviruses associated with outbreaks of acute gastroenteritis in the United States, 2000–2004. J Infect Dis. 2006;193(3):413–21. pmid:16388489.
  21. 21. Fankhauser RL, Monroe SS, Noel JS, Humphrey CD, Bresee JS, Parashar UD, et al. Epidemiologic and molecular trends of "Norwalk-like viruses" associated with outbreaks of gastroenteritis in the United States. J Infect Dis. 2002;186(1):1–7. pmid:12089655.
  22. 22. Kroneman A, Vega E, Vennema H, Vinje J, White PA, Hansman G, et al. Proposal for a unified norovirus nomenclature and genotyping. Archives of virology. 2013;158(10):2059–68. Epub 2013/04/26. pmid:23615870.
  23. 23. LoBue AD, Lindesmith L, Yount B, Harrington PR, Thompson JM, Johnston RE, et al. Multivalent norovirus vaccines induce strong mucosal and systemic blocking antibodies against multiple strains. Vaccine. 2006;24(24):5220–34. pmid:16650512.
  24. 24. Zheng DP, Widdowson MA, Glass RI, Vinjé J. Molecular epidemiology of genogroup II-genotype 4 noroviruses in the United States between 1994 and 2006. J Clin Microbiol. 2010;48(1):168–77. pmid:19864482;
  25. 25. Jones MK, Grau KR, Costantini V, Kolawole AO, de Graaf M, Freiden P, et al. Human norovirus culture in B cells. Nature protocols. 2015;10(12):1939–47. Epub 2015/10/30. pmid:26513671;
  26. 26. Jones MK, Watanabe M, Zhu S, Graves CL, Keyes LR, Grau KR, et al. Enteric bacteria promote human and mouse norovirus infection of B cells. Science. 2014;346(6210):755–9. Epub 2014/11/08. pmid:25378626;
  27. 27. Moore MD, Goulter RM, Jaykus LA. Human norovirus as a foodborne pathogen: challenges and developments. Annual review of food science and technology. 2015;6:411–33. Epub 2015/04/18. pmid:25884284.
  28. 28. Straub TM, Honer zu Bentrup K, Orosz-Coghlan P, Dohnalkova A, Mayer BK, Bartholomew RA, et al. In vitro cell culture infectivity assay for human noroviruses. Emerg Infect Dis. 2007;13(3):396–403. Epub 2007/06/08. pmid:17552092;
  29. 29. Ettayebi K, Crawford SE, Murakami K, Broughman JR, Karandikar U, Tenge VR, et al. Replication of human noroviruses in stem cell-derived human enteroids. Science. 2016;353(6306):1387–93. Epub 2016/08/27. pmid:27562956.
  30. 30. Harrington PR, Lindesmith L, Yount B, Moe CL, Baric RS. Binding of Norwalk virus-like particles to ABH histo-blood group antigens is blocked by antisera from infected human volunteers or experimentally vaccinated mice. J Virol. 2002;76(23):12335–43. Epub 2002/11/05. pmid:12414974;
  31. 31. Reeck A, Kavanagh O, Estes MK, Opekun AR, Gilger MA, Graham DY, et al. Serological correlate of protection against norovirus-induced gastroenteritis. J Infect Dis. 2010;202(8):1212–8. pmid:20815703;
  32. 32. Huang P, Farkas T, Zhong W, Tan M, Thornton S, Morrow AL, et al. Norovirus and histo-blood group antigens: demonstration of a wide spectrum of strain specificities and classification of two major binding groups among multiple binding patterns. J Virol. 2005;79(11):6714–22. Epub 2005/05/14. pmid:15890909;
  33. 33. Singh BK, Leuthold MM, Hansman GS. Human noroviruses' fondness for histo-blood group antigens. J Virol. 2015;89(4):2024–40. Epub 2014/11/28. pmid:25428879;
  34. 34. Marionneau S, Cailleau-Thomas A, Rocher J, Le Moullac-Vaidye B, Ruvoen N, Clement M, et al. ABH and Lewis histo-blood group antigens, a model for the meaning of oligosaccharide diversity in the face of a changing world. Biochimie. 2001;83(7):565–73. Epub 2001/08/28. pmid:11522384.
  35. 35. Atmar RL, Bernstein DI, Lyon GM, Treanor JJ, Al-Ibrahim MS, Graham DY, et al. Serological Correlates of Protection against a GII.4 Norovirus. Clinical and vaccine immunology: CVI. 2015{Lindesmith, 2012 #52}. Epub 2015/06/05. pmid:26041041.
  36. 36. Tamminen K, Malm M, Vesikari T, Blazevic V. Mucosal Antibodies Induced by Intranasal but Not Intramuscular Immunization Block Norovirus GII.4 Virus-Like Particle Receptor Binding. Viral immunology. 2016;29(5):315–9. Epub 2016/05/03. pmid:27135874.
  37. 37. Johnson PC, Mathewson JJ, DuPont HL, Greenberg HB. Multiple-challenge study of host susceptibility to Norwalk gastroenteritis in US adults. J Infect Dis. 1990;161(1):18–21. Epub 1990/01/01. pmid:2153184.
  38. 38. Lindesmith LC, Donaldson E, Leon J, Moe CL, Frelinger JA, Johnston RE, et al. Heterotypic humoral and cellular immune responses following Norwalk virus infection. J Virol. 2010;84(4):1800–15. Epub 2009/12/17. pmid:20007270;
  39. 39. Lindesmith L, Moe C, Marionneau S, Ruvoen N, Jiang X, Lindblad L, et al. Human susceptibility and resistance to Norwalk virus infection. Nature medicine. 2003;9(5):548–53. Epub 2003/04/15. pmid:12692541.
  40. 40. Ramani S, Neill FH, Opekun AR, Gilger MA, Graham DY, Estes MK, et al. Mucosal and Cellular Immune Responses to Norwalk Virus. J Infect Dis. 2015;212(3):397–405. Epub 2015/01/31. pmid:25635121;
  41. 41. Malm M, Tamminen K., Vesikari T, and Blazevic T. Comparison of intramuscular, intranasal, and combined administration of norovirus virus-like particle subunit vaccine candidate for induction of protective immune responses in mice. Journal of Clinical and Cellular Immunology. 2015;6(1):284.
  42. 42. Lindesmith LC, Debbink K, Swanstrom J, Vinjé J, Costantini V, Baric RS, et al. Monoclonal antibody-based antigenic mapping of norovirus GII.4-2002. J Virol. 2012;86(2):873–83. pmid:22090098;
  43. 43. Lindesmith LC, Costantini V, Swanstrom J, Debbink K, Donaldson EF, Vinjé J, et al. Emergence of a norovirus GII.4 strain correlates with changes in evolving blockade epitopes. J Virol. 2013;87(5):2803–13. pmid:23269783;
  44. 44. Atmar RL, Opekun AR, Gilger MA, Estes MK, Crawford SE, Neill FH, et al. Determination of the 50% human infectious dose for Norwalk virus. J Infect Dis. 2014;209(7):1016–22. Epub 2013/11/21. pmid:24253285;
  45. 45. Czako R, Atmar RL, Opekun AR, Gilger MA, Graham DY, Estes MK. Experimental human infection with Norwalk virus elicits a surrogate neutralizing antibody response with cross-genogroup activity. Clinical and vaccine immunology: CVI. 2015;22(2):221–8. Epub 2014/12/30. pmid:25540269;
  46. 46. Lindesmith LC, Ferris MT, Mullan CW, Ferreira J, Debbink K, Swanstrom J, et al. Broad Blockade Antibody Responses in Human Volunteers after Immunization with a Multivalent Norovirus VLP Candidate Vaccine: Immunological Analyses from a Phase I Clinical Trial. PLoS Med. 2015;12(3):e1001807. pmid:25803642.
  47. 47. Parker TD, Kitamoto N, Tanaka T, Hutson AM, Estes MK. Identification of Genogroup I and Genogroup II broadly reactive epitopes on the norovirus capsid. J Virol. 2005;79(12):7402–9. Epub 2005/05/28. pmid:15919896;
  48. 48. Treanor JJ, Atmar RL, Frey SE, Gormley R, Chen WH, Ferreira J, et al. A novel intramuscular bivalent norovirus virus-like particle vaccine candidate—reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults. J Infect Dis. 2014;210(11):1763–71. pmid:24951828.
  49. 49. LoBue AD, Thompson JM, Lindesmith L, Johnston RE, Baric RS. Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge. J Virol. 2009;83(7):3212–27. Epub 2009/01/30. pmid:19176631;
  50. 50. Bok K, Parra GI, Mitra T, Abente E, Shaver CK, Boon D, et al. Chimpanzees as an animal model for human norovirus infection and vaccine development. Proc Natl Acad Sci U S A. 2011;108(1):325–30. pmid:21173246;
  51. 51. Plotkin SA, Orenstein WA, Offit PA. Vaccines. 5th ed. Philadelphia, Pa: Saunders/Elsevier; 2008. xvii, 1725 p. p.
  52. 52. Velasquez LS, Hjelm BE, Arntzen CJ, Herbst-Kralovetz MM. An intranasally delivered Toll-like receptor 7 agonist elicits robust systemic and mucosal responses to Norwalk virus-like particles. Clinical and vaccine immunology: CVI. 2010;17(12):1850–8. Epub 2010/10/22. pmid:20962211;
  53. 53. Wang X, Ku Z, Dai W, Chen T, Ye X, Zhang C, et al. A bivalent virus-like particle based vaccine induces a balanced antibody response against both enterovirus 71 and norovirus in mice. Vaccine. 2015;33(43):5779–85. Epub 2015/10/02. pmid:26424606.
  54. 54. Kocher J, Bui T, Giri-Rachman E, Wen K, Li G, Yang X, et al. Intranasal P particle vaccine provided partial cross-variant protection against human GII.4 norovirus diarrhea in gnotobiotic pigs. J Virol. 2014;88(17):9728–43. Epub 2014/06/13. pmid:24920797;